Shao, S. et al. Diabetes and general survival amongst breast most cancers sufferers within the US army well being system. Most cancers Epidemiol. Biomarkers Prev. 27, 50–57 (2018).
Lee, Okay. N. et al. Kind 2 diabetes, breast most cancers particular and general mortality: Associations by metformin use and modification by race, physique mass, and estrogen receptor standing. PLoS ONE 15, e0232581 (2020).
Luo, J. et al. Pre-existing diabetes and breast most cancers prognosis amongst aged girls. Br. J. Most cancers 113, 827–832 (2015).
Nelson, H. D. Generally used sorts of postmenopausal estrogen for therapy of sizzling flashes: scientific evaluation. JAMA 291, 1610–1620 (2004).
Maclennan, A. H., Broadbent, J. L., Lester, S. & Moore, V. Oral oestrogen and mixed oestrogen/progestogen remedy versus placebo for warm flushes. Cochrane Database Syst. Rev. 2004, CD002978 (2004).
The 2022 Hormone Remedy Place Assertion of The North American Menopause Society” Advisory Panel. The 2022 hormone remedy place assertion of The North American Menopause Society. Menopause 29, 767–794 (2022).
Stuenkel, C. A. et al. Remedy of signs of the menopause: An endocrine society medical apply guideline. J. Clin. Endocrinol. Metab. 100, 3975–4011 (2015).
McVicker, L. et al. Vaginal estrogen remedy use and survival in females with breast most cancers. JAMA Oncol. 10, 103–108 (2024).
Beral, V. & Million,. Girls Examine Collaborators. Breast most cancers and hormone-replacement remedy within the Million Girls Examine. The Lancet 362, 419–427 (2003).
Henderson, B. E., Paganini-Hill, A. & Ross, R. Okay. Decreased mortality in customers of estrogen substitute remedy. Arch. Intern. Med. 151, 75–78 (1991).
Fletcher, A. S. et al. Use of hormone substitute remedy (HRT) and survival following breast most cancers analysis. Breast 14, 192–200 (2005).
Newcomb, P. A. et al. Prediagnostic use of hormone remedy and mortality after breast most cancers. Most cancers Epidemiol. Biomarkers Prev. 17, 864–871 (2008).
Rosenberg, L. U. et al. Menopausal hormone remedy in relation to breast most cancers traits and prognosis: A cohort research. Breast Most cancers Res. 10, R78 (2008).
Rauh, C. et al. Hormone remedy and its impact on the prognosis in breast most cancers sufferers. Geburtshilfe Frauenheilkd 75, 588–596 (2015).
Schuetz, F. et al. Decreased incidence of distant metastases and decrease mortality in 1072 sufferers with breast most cancers with a historical past of hormone substitute remedy. Am. J. Obstet. Gynecol. 196(342), e1-9 (2007).
Sener, S. F. et al. The results of hormone substitute remedy on postmenopausal breast most cancers biology and survival. Am. J. Surg. 197, 403–407 (2009).
Obi, N. et al. Relationship between menopausal hormone remedy and mortality after breast most cancers The MARIEplus research, a potential case cohort. Int. J. Most cancers 138, 2098–2108 (2016).
Strickland, D. M., Gambrell, R. D., Butzin, C. A. & Strickland, Okay. The connection between breast most cancers survival and prior postmenopausal estrogen use. Obstet. Gynecol. 80, 400–404 (1992).
Manson, J. E. et al. Menopausal hormone remedy and well being outcomes through the intervention and prolonged poststopping phases of the Girls’s Well being Initiative randomized trials. JAMA 310, 1353–1368 (2013).
Anagnostis, P. et al. Menopausal hormone remedy and cardiovascular danger: The place are we now?. Curr. Vasc. Pharmacol. 17, 564–572 (2019).
Wolf, P. H., Madans, J. H., Finucane, F. F., Higgins, M. & Kleinman, J. C. Discount of cardiovascular disease-related mortality amongst postmenopausal girls who use hormones: Proof from a nationwide cohort. Am. J. Obstet. Gynecol. 164, 489–494 (1991).
Grodstein, F. A potential, observational research of postmenopausal hormone remedy and first prevention of heart problems. Ann. Intern. Med. 133, 933 (2000).
Petitti, D. B., Sidney, S. & Quesenberry, C. P. Hormone substitute remedy and the danger of myocardial infarction in girls with coronary danger components. Epidemiology 11, 603–606 (2000).
Rossouw, J. E. et al. Dangers and advantages of estrogen plus progestin in wholesome postmenopausal girls: Principal outcomes from the ladies’s well being initiative randomized managed trial. JAMA 288, 321–333 (2002).
Nie, G. et al. The results of menopause hormone remedy on lipid profile in postmenopausal girls: A scientific evaluation and meta-analysis. Entrance. Pharmacol. 12, 850815 (2022).
Sund, R. High quality of the finnish hospital discharge register: A scientific evaluation. Scand. J. Public Well being 40, 505–515 (2012).
Pukkala, E. et al. Nordic most cancers registries—An summary of their procedures and information comparability. Acta Oncol. 57, 440–455 (2018).
Lahti, R. A. & Penttilä, A. The validity of loss of life certificates: Routine validation of loss of life certification and its results on mortality statistics. Forensic Sci. Int. 115, 15–32 (2001).
Stahlberg, C. et al. Breast most cancers incidence, case-fatality and breast most cancers mortality in Danish girls utilizing hormone substitute remedy–a potential observational research. Int. J. Epidemiol. 34, 931–935 (2005).
Ewertz, M., Gillanders, S., Meyer, L. & Zedeler, Okay. Survival of breast most cancers sufferers in relation to components which have an effect on the danger of growing breast most cancers. Int. J. Most cancers 49, 526–530 (1991).
Yu, X. et al. Hormone substitute remedy and breast most cancers survival: A scientific evaluation and meta-analysis of observational research. Breast Most cancers 24, 643–657 (2017).
Britt, Okay. L., Cuzick, J. & Phillips, Okay. A. Key steps for efficient breast most cancers prevention. Nat. Rev. Most cancers 20, 417–436 (2020).
Zaluzec, E. Okay. & Sempere, L. F. Systemic and native methods for major prevention of breast most cancers. Cancers 16, 248 (2024).
Kotsopoulos, J. et al. Bilateral oophorectomy and all-cause mortality in girls with BRCA1 and BRCA2 sequence variations. JAMA Oncol. 10, 484–492 (2024).
Palme, M. & Simeonova, E. Does girls’s training have an effect on breast most cancers danger and survival? Proof from a inhabitants based mostly social experiment in training. J. Well being Econ. 42, 115–124 (2015).
Magnusson, C., Holmberg, L., Nordén, T., Lindgren, A. & Persson, I. Prognostic traits in breast cancers after hormone substitute remedy. Breast Most cancers Res. Deal with 38, 325–334 (1996).
Godina, C. et al. Prognostic impression of menopausal hormone remedy in breast most cancers differs in keeping with tumor traits and therapy. Entrance. Oncol. 10, 80 (2020).
Inexperienced, J. et al. Cohort profile: The million girls research. Int. J. Epidemiol. 48, 28–29e (2019).
Harman, S. M. et al. Timing and period of menopausal hormone therapy could have an effect on cardiovascular outcomes. Am. J. Med. 124, 199–205 (2011).
Nudy, M., Chinchilli, V. M. & Foy, A. J. A scientific evaluation and meta-regression evaluation to look at the ‘timing speculation’ of hormone substitute remedy on mortality, coronary coronary heart illness, and stroke. Int. J. Cardiol. Coronary heart Vasc. 22, 123–131 (2019).
von Elm, E. et al. The strengthening the reporting of observational research in epidemiology (STROBE) assertion: Pointers for reporting observational research. J. Clin. Epidemiol. 61, 344–349 (2008).
Arffman, M. et al. FinDM database on diabetes in Finland. (2020).
Sund, R., Harno, Okay., Ranta, S. & Tolppanen, E. Analysis of case inclusion in two population-based diabetes registers. Finn. J. eHealth eWelfare 2, 136–146 (2010).
Putter, H., Fiocco, M. & Geskus, R. B. Tutorial in biostatistics: Competing dangers and multi-state fashions. Stat. Med. 26, 2389–2430 (2007).
deGlas, N. A. et al. Performing survival analyses within the presence of competing dangers: A medical instance in older breast most cancers sufferers. J. Nat. Most cancers Inst. 108, 1 (2016).
Grambsch, P. M. & Therneau, T. M. Proportional hazards exams and diagnostics based mostly on weighted residuals. Biometrika 81, 515–526 (1994).
Therneau, T. _A Package deal for Survival Evaluation in S_version 2.38. (2015).
Staff, R. C. R: A language and setting for statistical computing. (R Basis for Statistical Computing, 2017).
